author-photo

Ajay K. Nooka

Emory University Hospital

6

Papers

49

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
The Piper Phase 4 Study: Pathogen Inactivated Platelets Entering Routine Practice

2021
Show All
- Source
- Cite
- Save
Citations (0)
P-170: Transplant related morbidities with Melphalan as conditioning regimen for myeloma autotransplants

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (20)
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (20)
DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)